gsk163090
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00435695)
Timeline
Indications
Mechanism of action
- Serotonin 1b (5-HT1b) receptorANTAGONIST
HTR1B antagonist
- Serotonin 1d (5-HT1d) receptorANTAGONIST
HTR1D antagonist
- Serotonin 1a (5-HT1a) receptorANTAGONIST
HTR1A antagonist
- Serotonin transporterANTAGONIST
SLC6A4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1- Mol. weight
- 415.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1631540 ↗
Also known as
- 1-(3-(2-(4-(2-methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone
- gsk163090
- gsk163090
- gsk163090
- gsk163090
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00896363 | Phase 2 | Apr 1, 2009 | GlaxoSmithKline |
| NCT00559299 | Phase 1 | Nov 1, 2007 | GlaxoSmithKline |
| NCT00536679 | Phase 1 | Sep 1, 2007 | GlaxoSmithKline |
| NCT00435695 | Phase 1 | Nov 1, 2006 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2006 |
1 organizations
Page 1 / 1